For example, the recent Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) study has shown that eplerenone, an MR antagonist, has beneficial effects in patients with moderate heart failure (NYHA class II) [9]. The gene discussed is NR3C2; the disease is heart failure.